Shown verbatim: the complete text as captured from the official PDF posted by the West Virginia Legislature, fetched 2026-09-25. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
WEST VIRGINIA LEGISLATURE
2026 REGULAR SESSION
Enrolled
Senate Bill 906
BY SENATOR DEEDS
[Passed March 14, 2026; in effect 90 days from
passage (June 12, 2026)]
Enr SB 906
1 AN ACT to amend and reenact §60A-2-201 and §60A-2-204 of the Code of West Virginia, 1931,
2 as amended, relating to permitting the lawful prescription, distribution, and marketing of
3 any composition of crystalline polymorph psilocybin that the United States Food and Drug
4 Administration approves and that is rescheduled by the United States Drug Enforcement
5 Administration.
Be it enacted by the Legislature of West Virginia:
ARTICLE 2. STANDARDS AND SCHEDULES.
§60A-2-201. Authority of Board of Pharmacy; recommendations to Legislature.
1 (a) The Board of Pharmacy shall administer the provisions of this chapter. It shall also, on
2 the first day of each regular legislative session, recommend to the Legislature which substances
3 should be added to or deleted from the schedules of controlled substances contained in this article
4 or reschedule therein. The Board of Pharmacy shall also have the authority between regular
5 legislative sessions, on an emergency basis, to add to or delete from the schedules of controlled
6 substances contained in this article or reschedule such substances based upon the
7 recommendations and approval of the federal food, drug and cosmetic agency, and shall report
8 such actions on the first day of the regular legislative session immediately following said actions.
9 In making any such recommendation regarding a substance, the Board of Pharmacy shall
10 consider the following factors:
11 (1) The actual or relative potential for abuse;
12 (2) The scientific evidence of its pharmacological effect, if known;
13 (3) The state of current scientific knowledge regarding the substance;
14 (4) The history and current pattern of abuse;
15 (5) The scope, duration and significance of abuse;
16 (6) The potential of the substance to produce psychic or physiological dependence liability;
17 and
1
Enr SB 906
18 (7) Whether the substance is an immediate precursor of a substance already controlled
19 under this article.
20 (b) After considering the factors enumerated in subsection (a) of this section, the Board of
21 Pharmacy shall make findings with respect to the substance under consideration. If it finds that
22 any substance not already controlled under any schedule has a potential for abuse, it shall
23 recommend to the Legislature that the substance be added to the appropriate schedule. If it finds
24 that any substance already controlled under any schedule should be rescheduled or deleted, it
25 shall so recommend to the Legislature.
26 (c) If the Board of Pharmacy designates a substance as an immediate precursor,
27 substances which are precursors of the controlled precursor shall not be subject to control solely
28 because they are precursors of the controlled precursor.
29 (d) If any substance is designated, rescheduled, or deleted as a controlled substance
30 under federal laws and notice thereof is given to the Board of Pharmacy, the board shall
31 recommend similar control of such substance to the Legislature, specifically stating that such
32 recommendation is based on federal action and the reasons why the federal government deemed
33 such action necessary and proper.
34 (e) The authority vested in the board by subsection (a) of this section shall not extend to
35 distilled spirits, wine, malt beverages, or tobacco as those terms are defined or used in other
36 chapters of this code nor to any nonnarcotic substance if such substance may under the Federal
37 Food, Drug and Cosmetic Act and the law of this state lawfully be sold over the counter without a
38 prescription.
39 (f) Notwithstanding any provision of this chapter to the contrary, the sale, wholesale,
40 distribution, or prescribing of a cannabidiol or nabiximols in a product approved by the Food and
41 Drug Administration is permitted and shall be placed on the schedule or descheduled as provided
42 for by the Drug Enforcement Administration.
2
Enr SB 906
43 (g) Notwithstanding §60A-2-204(d) of this code, if a drug that contains, an organic
44 psilocybin substance or the pharmaceutical composition of crystalline polymorph psilocybin, is
45 approved by the United States Food and Drug Administration and rescheduled by the United
46 States Drug Enforcement Administration it shall be lawful to prescribe, distribute, and market
47 based upon the recommendations of the United States Food and Drug Administration.
§60A-2-204. Schedule I.
1 (a) Schedule I shall consist of the drugs and other substances, by whatever official name,
2 common or usual name, chemical name, or brand name designated, listed in this section including
3 their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the
4 existence of such isomers, esters, ethers, and salts is possible within the specific chemical
5 designation.
6 (b) Opiates.
7 Acetyl-alpha-methylfentanyl(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-
8 phenylacetamide);
9 Acetylmethadol;
10 Allylprodine;
11 Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha-
12 acetylmethadol, levomethadyl acetate, or LAAM);
13 Alphameprodine;
14 Alphamethadol;
15 Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide;
16 1-(1-methyl-2-phenylethyl)-4-(( propanilido) piperidine);
17 Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-
18 phenylpropanamide);
19 Benzethidine;
20 Betacetylmethadol;
3
Enr SB 906
21 Beta-hydroxyfentanyl(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-
22 phenylpropanamide);
23 Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-
24 piperidinyl]-N-phenylpropanamide);
25 Betameprodine;
26 Betamethadol;
27 Betaprodine;
28 Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-
29 2-one);
30 Clonitazene;
31 Dextromoramide;
32 Diampromide;
33 Diethylthiambutene;
34 Difenoxin;
35 Dimenoxadol;
36 Dimepheptanol;
37 Dimethylthiambutene;
38 Dioxaphetyl butyrate;
39 Dipipanone;
40 Ethylmethylthiambutene;
41 Etonitazene;
42 Etoxeridine;
43 Fentanyl analog or derivative, as that term is defined in article one of this chapter:
44 Provided, That fentanyl and carfentanil remains a Schedule II substance, as set forth in §60A-2-
45 206 of this code;
46 Furethidine;
4
Enr SB 906
47 Hydroxypethidine;
48 Ketobemidone;
49 Levomoramide;
50 Levophenacylmorphan;
51 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
52 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-phenylpropanamide);
53 Morpheridine;
54 N-Methylnorfentanyl (N-(1-Methyl-4-piperidinyl)-N-phenyl-propanamide,
55 monohydrochloride);
56 MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
57 Noracymethadol;
58 Norlevorphanol;
59 Normethadone;
60 Norpipanone;
61 Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide);
62 PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
63 Phenadoxone;
64 Phenampromide;
65 Phenomorphan;
66 Phenoperidine;
67 Piritramide;
68 Proheptazine;
69 Properidine;
70 Propiram;
71 Racemoramide;
72 Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
5
Enr SB 906
73 Tilidine;
74 Trimeperidine.
75 (c) Opium derivatives.
76 Acetorphine;
77 Acetyldihydrocodeine;
78 Benzylmorphine;
79 Codeine methylbromide;
80 Codeine-N-Oxide;
81 Cyprenorphine;
82 Desomorphine;
83 Dihydromorphine;
84 Drotebanol;
85 Etorphine (except HCl Salt);
86 Heroin;
87 Hydromorphinol;
88 Methyldesorphine;
89 Methyldihydromorphine;
90 Morphine methylbromide;
91 Morphine methylsulfonate;
92 Morphine-N-Oxide;
93 Myrophine;
94 Nicocodeine;
95 Nicomorphine;
96 Normorphine;
97 Pholcodine;
98 Thebacon.
6
Enr SB 906
99 (d) Hallucinogenic substances.
100 Alpha-ethyltryptamine; some trade or other names: etryptamine; Monase; alpha-ethy-1H-indole-
101 3-ethanamine; 3-(2- aminobutyl) indole; alpha-ET; and AET;
102 1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names: para-methoxymethamphetamine,
103 PMMA);
104 4-bromo-2, 5-dimethoxy-amphetamine; some trade or other names: 4-bromo-2,5-
105 dimethoxy-alpha-methylphenethylamine; 4-bromo- 2,5-DMA;
106 4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names: 2-(4-bromo-2,5-
107 dimethoxyphenyl)-1-aminoethane; alpha- desmethyl DOB; 2C-B, Nexus;
108 N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine. The substance has the
109 acronym 25B-NBOMe;
110 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe);
111 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);
112 2,5-dimethoxyamphetamine; some trade or other names: 2,5-dimethoxy-alpha-
113 methylphenethylamine; 2,5-DMA;
114 2,5-dimethoxy-4-ethylamphet-amine; some trade or other names: DOET;
115 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
116 4-methoxyamphetamine; some trade or other names: 4-methoxy-alpha-
117 methylphenethylamine; paramethoxyamphetamine; PMA;
118 3-Hydoxy-phencyclidine (other name hydroxy PCP);
119 5-methoxy-3, 4-methylenedioxy-amphetamine;
120 4-methyl-2,5-dimethoxy-amphetamine; some trade and other names: 4-methyl-2,5-
121 dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";
122 3,4-methylenedioxy amphetamine;
123 3,4-methylenedioxymethamphetamine (MDMA);
7
Enr SB 906
124 3,4-methylenedioxy-N-ethylamphetamine (also known as ( ethyl-alpha-methyl-3,4
125 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
126 N-hydroxy-3,4-methylenedioxyamphetamine (also known as ( hydroxy-alpha-methyl-3,4
127 (methylenedioxy) phenethylamine, and ( hydroxy MDA);
128 3,4,5-trimethoxy amphetamine;
129 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
130 Alpha-methyltryptamine (other name: AMT);
131 Bufotenine; some trade and other names: 3-(beta-Dimethylaminoethyl)-5-
132 hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-
133 dimethyltryptamine; mappine;
134 Diethyltryptamine; sometrade and other names: N, N-Diethyltryptamine; DET;
135 Dimethyltryptamine; some trade or other names: DMT;
136 5-Methoxy-N,N-disopropyltryptamine (5-MeO-DIPT);
137 Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-
138 2-methoxy-6, 9-methano-5H- pyrido [1’, 2’: 1, 2] azepino [5,4-b] indole; Tabernanthe iboga;
139 Lysergic acid diethylamide;
140 Marihuana; Marijuana (Cannabis, sp.);
141 Mescaline;
142 Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-
143 6, 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
144 Peyote; meaning all parts of the plant presently classified botanically as Lophophora
145 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
146 plant, and every compound, manufacture, salts, immediate derivative, mixture, or preparation of
147 such plant, its seeds or extracts;
148 N-ethyl-3-piperidyl benzilate;
149 N-methyl-3-piperidyl benzilate;
8
Enr SB 906
150 Psilocybin; except as provided for in §60A-2-201(g) of this code;
151 Psilocyn;
152 Tetrahydrocannabinols; synthetic equivalents of the substances contained in the plant, or
153 in the resinous extractives of Cannabis, sp. and/or synthetic substances, immediate derivatives
154 and their isomers with similar chemical structure and pharmacological activity including, but not
155 limited to the following:
156 delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;
157 delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;
158 delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;
159 delta-8 Cis or trans tetrahydrocannabinol and its optical isomers; and
160 delta-10 Cis or trans tetrahydrocannabinol and its optical isomers;
161 (Since nomenclature of these substances is not internationally standardized, compounds
162 of these structures, regardless of numerical designation of atomic positions covered.)
163 Delta-8-tetrahydrocannabinol-O (delta-8-THC-0), Delta-9-tetrahydrocannabinol (delta-9-
164 THC-0) and Synthetic and non-naturally occurring cannabinoids.
165 The provisions of this section related to tetrahydrocannabinols are inapplicable to
166 products or substances lawfully manufactured, distributed, or possessed under the provisions of
167 §19-12E-1 et seq. and chapter 16H of this code.
168 Ethylamine analog of phencyclidine; some trade or other names: N-ethyl-1-
169 phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine,
170 cyclohexamine, PCE;
171 Pyrrolidine analog of phencyclidine; some trade or other names: 1-(1-phenylcyclohexyl)-
172 pyrrolidine, PCPy, PHP;
173 Thiophene analog of phencyclidine; some trade or other names: 1-[1-(2-thienyl)-
174 cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine; TPCP, TCP;
175 1[1-(2-thienyl)cyclohexyl]pyrroldine; some other names: TCPy;
9
Enr SB 906
176 4-methylmethcathinone (Mephedrone);
177 3,4-methylenedioxypyrovalerone (MDPV);
178 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
179 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
180 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
181 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
182 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
183 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
184 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
185 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
186 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
187 3,4-Methylenedioxy-N-methylcathinone (Methylone);
188 2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-T-7, itsoptical isomers, salts and
189 salts of isomers;
190 5-methoxy-N,N-dimethyltryptamine some trade or other names: 5-methoxy-3-[2-
191 (dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT);
192 Alpha-methyltryptamine (other name: AMT);
193 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);
194 Synthetic Cannabinoids as follows:
195 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol) { also known as CP
196 47,497 and homologues} ;
197 rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol { also known as CP
198 47,497-C8 homolog} ;
199 [(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a-
200 tetrahydrobenzo[c]chromen-1-ol)] { also known as HU-210} ;
201 (dexanabinol);
10
Enr SB 906
202 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
203 tetrahydrobenzol[c]chromen-1-ol) { also known as HU-211} ;
204 1-Pentyl-3-(1-naphthoyl)indole { also known as JWH-018} ;
205 1-Butyl-3-(1-naphthoyl)indole { also known as JWH-073} ;
206 (2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone { also known as JWH-015} ;
207 (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone { also known as JWH-019} ;
208 [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone { also known as
209 JWH-200} ;
210 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone { also known as JWH-250} ;
211 2-((1S,2S,5S)-5-hydroxy-2-(3-hydroxtpropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol
212 {also known as CP 55,940} ;
213 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl)-methanone { also known as JWH-
214 122};
215 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl)-methanone { also known as JWH-398;
216 (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone { also known as RCS-4} ;
217 1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone { also known as
218 RCS-8} ;
219 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
220 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
221 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
222 Synthetic cannabinoids:
223 CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
224 YL)phenol);
225 HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
226 10A-tetrahydrobenzo[C] chromen-1-OL)];
11
Enr SB 906
227 HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2-
228 YL)-6A,7,10,10atetrahydrobenzo[ C]chromen-1-OL);
229 JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
230 JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
231 JWH-073, 1-butyl-3-(1-naphthoyl)indole;
232 JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
233 JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]
234 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-
235 ADB);
236 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
237 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (FUB-
238 AMB);
239 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
240 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
241 (ADB-FUBINACA);
242 Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
243 (MDMB-CHMICA);
244 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
245 (MDMB-FUBINACA);
246 Tetrahydrocannabinols:
247 DELTA-1 CIS OR trans tetrahydrocannabinol and their optical isomers.
248 DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
249 DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
250 Synthetic Phenethylamines
251 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe/ 2C-I-
252 NBOMe);
12
Enr SB 906
253 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C-
254 NBOMe);
255 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B-
256 NBOMe);
257 Synthetic Opioids (including their isomers, esters, ethers, salts and salts of isomers, esters
258 and ethers):
259 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
260 furanyl fentanyl;
261 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-
262 47700);
263 N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-
264 phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
265 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethylpiperidin-4-yl]-N-phenylpropionamide, also known
266 as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, (beta-
267 hydroxythiofentanyl);
268 N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl);
269 N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
270 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl);
271 2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide
272 (also known as U-48800);
273 Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as
274 U-49900);
275 Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also
276 known as U-51754);
277 2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine
278 (butonitazene);
13
Enr SB 906
279 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (etodesnitazene);
280 N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
281 (flunitazene);
282 N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
283 (metodesnitazene);
284 N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
285 (metonitaze);
286 2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1 H-benzimidazole (N-pyrrolidino
287 etonitazene, etonitazepyne);
288 N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
289 (protonitazene);
290 N-pyrrolidino etonitazene;
291 Etodesnitazene;
292 Isotonitazene;
293 Protonitazene;
294 Metonitazene;
295 Butonitazene;
296 Metodesnitazene;
297 Flunitazene;
298 Opioid Receptor Agonist
299 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one)
300 AH-7921 (3,4-dichloro-N-(1dimethylamino)cyclohexylmethyl]benzamide).
301 Naphthoylindoles or any compound containing a 3-(-1-Napthoyl) indole structure with
302 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
303 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
304 include the following:
14
Enr SB 906
305 JWH 015;
306 JWH 018;
307 JWH 019;
308 JWH 073;
309 JWH 081;
310 JWH 122;
311 JWH 200;
312 JWH 210;
313 JWH 398;
314 AM 2201; and
315 WIN 55,212.
316 Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl) methane
317 structure with a substitution at the nitrogen atom of the indole ring whether or not further
318 substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to
319 any extent. This shall include, but not be limited to, JWH 175 and JWH 184.
320 Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole structure with
321 substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole
322 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
323 include, but not be limited to, JWH 147 and JWH 307.
324 Naphthylmethylindenes or any compound containing a Naphthylideneindene structure
325 with substitution at the 3- Position of the indene ring whether or not further substituted in the
326 indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. This
327 shall include, but not be limited to, JWH 176.
328 Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with
329 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
15
Enr SB 906
330 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include
331 the following:
332 RCS-8, SR-18 OR BTM-8;
333 JWH 250;
334 JWH 203;
335 JWH 251; and
336 JWH 302.
337 Cyclohexylphenols or any compound containing a 2-(3-hydroxycyclohexyl) phenol
338 structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the
339 cyclohexyl ring to any extent. This shall include the following:
340 CP 47,497 and its homologues and analogs;
341 Cannabicyclohexanol; and
342 CP 55,940.
343 Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with
344 substitution at the nitrogren atom of the indole ring whether or not further substituted in the indole
345 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include
346 the following:
347 AM 694;
348 Pravadoline WIN 48,098;
349 RCS 4; and
350 AM 679.
351 [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1-
352 napthalenymethanone. This shall include WIN 55,212-2.
353 Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol
354 structure with substitution on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051,
355 and JWH 133.
16
Enr SB 906
356 Adamantoylindoles or any compound containing a 3-(-1-Adamantoyl) indole structure with
357 substitution at the nitrogen atom of the indole ring whether or not further substituted in the
358 adamantoyl ring system to any extent. This shall include AM1248.
359 Tetramethylcyclopropylindoles or any compound containing A 3-
360 tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring
361 whether or not further substituted in the indole ring to any extent and whether or not substituted
362 in the tetramethylcyclopropyl ring to any extent. This shall include UR-144 and XLR-11.
363 N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.
364 Any other synthetic chemical compound that is a cannabinoid receptor type 1 agonist as
365 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV,
366 and V, not federal Food and Drug Administration-approved drug or used within legitimate,
367 approved medical research. Since nomenclature of these substances is not internationally
368 standardized, any immediate precursor or immediate derivative of these substances shall be
369 covered.
370 Tryptamines:
371 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
372 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
373 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT);
374 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
375 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT);
376 5-methoxy-α-methyltryptamine (5-MeO-AMT);
377 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT);
378 4-hydroxy Diethyltryptamine (4-HO-DET);
379 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
380 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT);
381 4-hydroxy Diethyltryptamine (4-HO-DET);
17
Enr SB 906
382 FDU-PB-22 (1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
383 FUB-PB-22 (Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
384 5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);
385 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
386 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
387 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
388 Methyl-Ethylaminopentiophenone;
389 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
390 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
391 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
392 carboxamide);
393 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
394 methylbutanoat);
395 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
396 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
397 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
398 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
399 Methyl-Ethylaminopentiophenone;
400 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
401 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
402 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
403 carboxamide);
404 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
405 methylbutanoat);
406 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
18
Enr SB 906
407 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3-
408 a][1,4]benzodiazepine);
409 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-
410 benzodiazepin-2-one);
411 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-
412 a][1,4]diazepine);
413 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
414 a][1,4]benzodiazepine);
415 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);
416 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
417 a][1,4]benzodiazepine);
418 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-
419 a][1,4]diazepine);
420 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-
421 one) ;
422 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine); and
423 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-
424 a][1,4]benzodiazepine).
425 (e) Depressants.
426 4-CN-CUMYL-BUTINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-
427 carboxamide);
428 Alpha-Phenylacetoacetonitrile (3-Oxo-2-phenylbutanenitrile);
429 2-Fluoro Deschloroketamine (2-(2-Fluorophenyl)-2-(methylamino)-cyclohexanone,
430 monohydrochloride);
431 4-MEAP (2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one);
432 Mecloqualone;
19
Enr SB 906
433 Methaqualone;
434 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
435 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3
436 a][1,4]benzodiazepine);
437 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-
438 benzodiazepin-2-one);
439 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-
440 a][1,4]diazepine);
441 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
442 a][1,4]benzodiazepine);
443 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);
444 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
445 a][1,4]benzodiazepine);
446 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-
447 a][1,4]diazepine);
448 gamma-hydroxybutyric acid (some other names include GHB; gamma-hydroxybutyrate;
449 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
450 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-
451 one);
452 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
453 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-
454 a][1,4]benzodiazepine);
455 Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
456 one); and
457 Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-
458 a][1,4]diazepine);
20
Enr SB 906
459 (f) Stimulants.
460 Aminorex; some other names: aminoxaphen; 2-amino-5- phenyl-2-oxazoline; or 4,5-
461 dihydro-5-phenyl-2-oxazolamine;
462 4,4'-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-
463 methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);
464 Cathinone; some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-
465 aminopropiophenone, 2-aminopropiophenone and norephedrone;
466 Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
467 Fenethylline;
468 Mesocarb (N-phenyl-N ′-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
469 Methcathinone, its immediate precursors and immediate derivatives, its salts, optical
470 isomers and salts of optical isomers; some other names: (2-(methylamino)-propiophenone; alpha-
471 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
472 methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypyrovalerone and/or
473 mephedrone;3,4-methylenedioxypyrovalerone (MPVD); ephedrone; N-methylcathinone;
474 methylcathinone; AL-464; AL-422; AL-463 and UR1432;
475 (+-) cis-4-methylaminorex; ((+-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
476 N-ethylamphetamine;
477 N,N-dimethylamphetemine; also known as N,N-alpha-trimethyl-benzeneethanamine;
478 N,N-alpha-trimethylphenethylamine;
479 Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and
480 salts of isomers;
481 Substituted amphetamines:
482 2-Fluoroamphetamine;
483 3-Fluoroamphetamine;
484 4-Fluoroamphetamine;
21
Enr SB 906
485 2-chloroamphetamine;
486 3-chloroamphetamine;
487 4-chloroamphetamine;
488 2-Fluoromethamphetamine;
489 3-Fluoromethamphetamine;
490 4-Fluoromethamphetamine;
491 4-chloromethamphetamine;
492 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
493 Alpha-PHP (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
494 MPHP (1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
495 PV8 (1-Phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
496 4-Chloro-Alpha-PVP (1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
497 N-Ethylhexedrone (2-(Ethylamino)-1-phenylhexan-1-one);
498 Methoxetamine (2-(Ethylamino)-2-(3-methoxyphenyl)-cyclohexanone); and
499 3-Fluorophenmetrazine (2-(3-Fluorophenyl)-3-methylmorpholine);
500 (g) Temporary listing of substances subject to emergency scheduling. Any material,
501 compound, mixture, or preparation which contains any quantity of the following substances:
502 N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts,
503 and salts of isomers;
504 N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical
505 isomers, salts, and salts of isomers.
506 N-benzylpiperazine, also known as BZP;
507 Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
508 4-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]-
509 butyramide);
510 Isobutyryl fentanyl (2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-propanamide);
22
Enr SB 906
511 Methoxyacetyl fentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-
512 acetamide);
513 3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-
514 phenylbutyramide);
515 4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
516 yl)butyramide);
517 Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-acetamide);
518 Tetrahydrofuran fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
519 carboxamide); and
520 Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide).
521 (h) The following controlled substances are included in Schedule I:
522 Synthetic Cathinones or any compound, except bupropion or compounds listed under a
523 different schedule, or compounds used within legitimate and approved medical research,
524 structurally derived from 2-Aminopropan-1-one by substitution at the 1-position with Monocyclic
525 or fused polycyclic ring systems, whether or not the compound is further modified in any of the
526 following ways:
527 By substitution in the ring system to any extent with Alkyl, alkylenedioxy, alkoxy, haloalkyl,
528 hydroxyl, or halide substituents whether or not further substituted in the ring system by one or
529 more other univalent substituents;
530 By substitution at the 3-position with an acyclic alkyl substituent;
531 By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl
532 groups;
533 By inclusion of the 2-amino nitrogen atom in a cyclic structure; or
534 Any other synthetic chemical compound that is a cannabinoid receptor type 1 agonist as
535 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV,
23
Enr SB 906
536 and V, not federal Food and Drug Administration-approved drug or used within legitimate,
537 approved medical research.
24
Enr SB 906
The Clerk of the Senate and the Clerk of the House of Delegates hereby
certify that the foregoing bill is correctly enrolled.
...............................................................
Clerk of the Senate
...............................................................
Clerk of the House of Delegates
Originated in the Senate.
In effect 90 days from passage.
...............................................................
President of the Senate
...............................................................
Speaker of the House of Delegates
__________
The within is ................................................ this the...........................................
Day of ..........................................................................................................., 2026.
.............................................................
Governor
25Every fact on this page links to its source, starting with the official bill record.